Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

2(33.3%)

N/A

2(33.3%)

Phase 3

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 1(2)

N/A(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04053842Phase 2Active Not Recruiting

Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy

Role: collaborator

NCT04644822Phase 3Completed

Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.

Role: lead

NCT03718260Not ApplicableUnknown

PSMA-PET Registry for Recurrent Prostate Cancer

Role: collaborator

NCT02514187Not ApplicableCompleted

A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients

Role: collaborator

NCT01738347Phase 1Completed

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Role: collaborator

NCT02134340Phase 1Completed

A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours

Role: lead

NCT01496391Completed

A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function

Role: lead

All 7 trials loaded